Thank you for being a Global Market News subscriber.
This Week’s Top Stories:
💉
Ozempic Users Report Sudden, Permanent Vision Loss. Now They’re Suing
A devastating complication is raising new questions about some of the world’s biggest weight-loss drugs.
💡Sponsor Spotlight
One of the best ways to win big in an investment is to buy into a company with big profit potential well before the rest of the market catches on.
It's not an opportunity that happens often, but when it does, substantial gains can be made.
This kind of opportunity is emerging right now in the commodity sector, specifically in copper and gold.
The world is changing, and those changes are causing the tide to rise in the commodity space to the point where gold and copper investments are making up the cornerstones of many portfolios.
And one largely unknown small-cap Canadian explorer focused in Australia is creating that opportunity today.
It has many of the hallmarks of a breakout story.
Funding from a major company
A substantial treasury
Assets in an established, safe jurisdiction
Aggressive drilling campaigns with plans for expansion
All of these are now converging as a compelling early-stage opportunity.
And the best part is that, despite everything, the company still trades for under a dollar.
That could quickly change once the broader market learns more about the potential of this company's projects.
Hence, the opportunity today.
You can see just what this company has, who runs it, and why it could command greater market attention as its projects advance.
💰
Social Security’s Cliff Is Getting Closer. The Average Retiree Could Eventually Lose Nearly $600 a Month
The deadline is getting harder to ignore. Here’s what the latest projections could mean for retirees, and why the eventual fix from Washington may matter just as much as the potential benefit cuts.
💡Sponsor Spotlight
Power of FDA Breakthrough Designation for Sepsis
The FDA doesn't grant Breakthrough Device Designation easily. It’s reserved for technologies with the potential to address life-threatening conditions, granting prioritized regulatory pathway.
Eliaz Therapeutics has earned this title for XGal-3®, an investigational sepsis device that is advancing toward human clinical trials next year.
This device targets Galectin-3, a protein that’s a key driver in the sepsis immune response, removing it directly from the bloodstream before organ failure sets in. Sepsis is a $100B/year problem, and there is currently no FDA-approved therapy that targets the cause. Not yet, at least.
Eliaz Therapeutics has 75+ patents across 30+ countries and a global collaboration with a world leader in medical technology, Terumo BCT.
☕
Starbucks Is Closing 250 Stores Across North America
Starbucks is shutting hundreds of locations as its turnaround takes another step. The closures offer a revealing look at what management believes needs to change.
🤝
Five Takeaways From Trump’s Summit With Xi That Investors Shouldn’t Ignore
The ceremony was friendly, but some of the biggest issues between Washington and Beijing remain unresolved. Trade, Taiwan, AI and semiconductors all gave investors something to watch.
💡Sponsor Spotlight
A Nasdaq Company Is Building AI That Even Its Own Operators Can’t See
AI's next infrastructure battle may not just be about faster chips.
It could be about who can see the data running through them.
Alpha Compute Corp. (Nasdaq: ALP) is building confidential computing infrastructure where data remains encrypted inside the processor and is designed to be inaccessible even to administrators and cloud operators.
Now the company has opened an early-access experience that lets investors see the technology in action.
🤬
Trump’s Rural Base Is Getting Frustrated With the Economy, New Poll Finds
Economic frustration is showing up in an important part of Trump’s political coalition. The poll offers a snapshot of how rural voters are viewing prices, jobs and the broader economy.
🌞
Happier Retirement May Come Down to These 3 Things.
Retirement planning usually revolves around money, but financial security is only part of the equation. Three less obvious factors may play an even bigger role in whether retirement actually feels rewarding.
Editor’s Note: Something New Is Coming Sundays
Starting Sunday, September 27, Global Market News will dedicate every Sunday issue to retirement and investing.
We’ll cover the financial issues that matter most as you approach or enjoy retirement, including dividend stocks, Social Security, Medicare, taxes, income strategies, inflation, portfolio ideas and ways to make your money last.
Our goal is simple: help you make smarter decisions with your money and get more out of retirement.
Look for the first issue next Sunday.
Know what you own, and know why you own it.
-Peter Lynch
You are receiving this email because you opted in to receive updates from Global Market News. This newsletter may contain sponsored content or advertisements. Information provided is for informational purposes only and should not be considered financial or investment advice. Always consult a financial advisor before making investment decisions.